<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03523377</url>
  </required_header>
  <id_info>
    <org_study_id>18-199</org_study_id>
    <nct_id>NCT03523377</nct_id>
  </id_info>
  <brief_title>Overnight Fasting After Completion of Therapy: The OnFACT Study</brief_title>
  <official_title>Overnight Fasting After Completion of Therapy: The OnFACT Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether regularly not eating for at least 14 hours&#xD;
      overnight (&quot;intermittent fasting&quot;) is feasible and can improve blood sugar.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2018</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The OnFACT study is a pilot randomized controlled trial of prolonged overnight fasting among adult survivors of childhood cancer.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participation completion</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of registered participants who successfully complete the 6-month intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>measure of glucose metabolism</measure>
    <time_frame>6 months</time_frame>
    <description>Assess the effect of prolonged overnight fasting on glucose metabolism, measured by glycosylated hemoglobin (HbA1c).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Childhood Cancer Survivors</condition>
  <arm_group>
    <arm_group_label>prolonged overnight fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the fasting arm will be instructed on how to use the SMS texting app to indicate the beginning and end of the nightly fast. In the first 2-4 weeks following randomization, intervention participants will complete three phone calls with study staff trained in motivational interviewing. These calls will be used to reinforce the prolonged overnight fasting instructions, identify barriers to prolonged overnight fasting, and support successes where they have occurred.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to the usual care arm will be instructed to eat a heart-healthy diet and exercise for at least 30 minutes five days a week, which is usual counseling in our clinics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>prolonged overnight fasting</intervention_name>
    <description>Three phone calls using motivational interviewing, support via SMS text.</description>
    <arm_group_label>prolonged overnight fasting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>usual care</intervention_name>
    <description>Eat a heart-healthy diet and exercise for at least 30 minutes five days a week</description>
    <arm_group_label>usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index is ≥ 18.5 kg/m^2&#xD;
&#xD;
          -  History of treatment for cancer or related illness diagnosed at ≤ 25 years old&#xD;
&#xD;
          -  Off of all cancer therapy for ≥ 2 years (excluding treatment for non-invasive or&#xD;
             superficial cancers)&#xD;
&#xD;
          -  History of radiation to the chest, abdomen or total body&#xD;
&#xD;
          -  Current age ≥18 years&#xD;
&#xD;
          -  English-speaking&#xD;
&#xD;
          -  Personal phone with SMS text messaging capability&#xD;
&#xD;
          -  Willingness to wear an mHealth device, such as a FitBit, for two 7-day periods&#xD;
&#xD;
          -  Able to perform all study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any antidiabetic, weight loss, or appetite control medication&#xD;
&#xD;
          -  Use of any other medication that could impact dietary intake, such as prednisone&#xD;
&#xD;
          -  Currently fasts 12 hours or more by self-report&#xD;
&#xD;
          -  Unable to fast due to medical reason such as pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danielle Friedman, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danielle Friedman, MD, MS</last_name>
    <phone>212-639-7376</phone>
    <email>friedmad@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chaya Moskowitz, PhD</last_name>
    <phone>646-888-8232</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Friedman, MD, MS</last_name>
      <phone>212-639-7376</phone>
    </contact>
    <investigator>
      <last_name>Danielle Friedman, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 1, 2018</study_first_submitted>
  <study_first_submitted_qc>May 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2018</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fasting</keyword>
  <keyword>18-199</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

